FrancophonIA/ELRC3.0 huggingface dataset:
English: In trials where the application sites were rotated as reflected in the instructions provided in SmPC and package leaflet, 35.7% of 830 patients using the Neupro transdermal patch, experienced application site reactions.
Latvian: Pētījumos, kuros aplikācijas vietas tika mainītas kā norādīts Zāļu aprakstā un Lietošanas instrukcijā, 35,7% no 830 pacientiem, kuri lietoja Neupro transdermālo plāksteri, novēroja reakcijas aplikācijas vietā.
English: At the beginning of the third week, you should take Neupro 6 mg (package marked with “Week 3”).
Latvian: Trešās nedēļas sākumā izmantojiet Neupro 6 mg (kārbiņa apzīmēta ar “3. nedēļa”).
English: AST, ALT, GGT), weight increased e, heart rate increased e, CPK increased d,e
Latvian: (ieskaitot ASAT, ALAT, GGT), palielināta ķermeņa masa e, paātrināta sirdsdarbība e, paaugstināts KFK līmenis d,e
English: The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of treatment with Neupro in only 4.3% of all subjects receiving Neupro.
Latvian: Lielākās daļas reakciju aplikācijas vietā intensitāte bija viegla vai vidēji izteikta, to novēroja tikai aplikācijas vietās un tā izraisīja ārstēšanas ar Neupro pārtraukšanu tikai 4,3% no visiem pacientiem, kuri saņēma Neupro.
English: Warnings and precautions Talk to your doctor or pharmacist before using Neupro.
Latvian: Brīdinājumi un piesardzība lietošanā Pirms Neupro lietošanas konsultējieties ar ārstu vai farmaceitu.
English: In trials where the application sites were rotated as reflected in the instructions provided in the SmPC and package leaflet, 34.2% of 748 patients using Neupro, experienced application site reactions.
Latvian: Pētījumos, kuros aplikācijas vietas tika mainītas kā norādīts Zāļu aprakstā un Lietošanas instrukcijā, 34,2% no 748 pacientiem, kuri lietoja Neupro, novēroja reakcijas aplikācijas vietā.
English: pathological gambling, stereotypy/ punding, binge eating/eating disorder b, compulsive shopping c)
Latvian: (ieskaitot patoloģisku aizraušanos ar azartspēlēm, stereotipiju/stereo tipas darbības, pārēšanos/ēšanas traucējumus b, nepārvaramu vēlmi iepirkties c)
English: Atrial fibrillation Supraventricular tachycardia
Latvian: Ātriju fibrilācija Supraventri kulāra tahikardija
English: hypersexuality, libido increased), confusional state, disorientationd, agitationd
Latvian: (ieskaitot hiperseksualitāti, paaugstinātu libido), apjukums, dezorientācija d,
English: Warnings and precautions Talk to your doctor, pharmacist or nurse before using Neupro.
Latvian: Brīdinājumi un piesardzība lietošanā Pirms Neupro lietošanas konsultējieties ar ārstu, farmaceitu vai medmāsu.
English: Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 748 Neupro- and 214 placebo-treated patients, 65.5% of the patients on Neupro and 33.2% of patients on placebo reported at least one adverse reaction.
Latvian: Balstoties uz apkopoto placebo kontrolēto klīnisko pētījumu analīzi, kas kopā ietvēra 748 pacientus, kuri ārstēti ar Neupro, un 214 pacientus, kuri ārstēti ar placebo; 65,5% pacientu, kuri saņēma Neupro, un 33,2% pacientu, kuri saņēma placebo, ir ziņots par vismaz vienu nevēlamu blakusparādību.
English: Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro are nausea, application site reactions, asthenic conditions and headache.
Latvian: Nevēlamas blakusparādības (NBP), par kurām tika ziņots vairāk nekā 10% pacientu, kuri tika ārstēti ar Neupro, ir šādas: slikta dūša, reakcijas aplikācijas vietā, astēniski stāvokļi un galvassāpes.
English: At the beginning of the second week, you should take Neupro 4 mg (package marked with “Week 2”).
Latvian: Otrās nedēļas sākumā izmantojiet Neupro 4 mg (kārbiņa apzīmēta ar “2. nedēļa”).
English: What Neupro contains The active substance is rotigotine.
Latvian: Neupro satur aktīvo vielu rotigotīnu.
English: Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,307 Neuproand 607 placebo-treated patients, 72.5% of the patients on Neupro and 58.0% of patients on placebo reported at least one adverse reaction.
Latvian: Balstoties uz apkopoto placebo kontrolēto klīnisko pētījumu analīzi, kas kopā ietvēra 1 307 pacientus, kuri ārstēti ar Neupro un 607 pacientus, kuri ārstēti ar placebo; 72,5% pacientu, kuri saņēma Neupro un 58,0% pacientu, kuri saņēma placebo, ir ziņots par vismaz vienu nevēlamu blakusparādību.
English: This includes seeing or hearing things that are not real (hallucinations), movements you cannot control related to Parkinson's disease (‘dyskinesia'), and swelling of legs and feet.
Latvian: Tādas blakusparādības ir, piemēram, neesošu lietu redzēšana vai dzirdēšana (halucinācijas), Parkinsona slimības izraisītas gribai nepakļautas kustības (diskinēzija), un kāju un pēdu pietūkums.
English: Side effects when using Neupro for Restless Legs Syndrome Tell your doctor or pharmacist if you notice any of the following side effects:
Latvian: Blakusparādības, lietojot Neupro Nemierīgo Kāju Sindroma ārstēšanai Pastāstiet savam ārstam vai farmaceitam, ja novērojat jebkādas sekojošas blakusparādības:
English: For most patients with early stage Parkinson's disease, the right dose is reached within 3 or 4 weeks, at doses of 6 mg per day or 8 mg per day, respectively.
Latvian: Lielākai daļai pacientu ar Parkinsona slimību agrīnā stadijā nepieciešamā deva tiek sasniegta 3 nedēļu laikā lietojot devu 6 mg vai 4 nedēļu laikā lietojot devu 8 mg dienā.
English: Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro transdermal patch are nausea, vomiting, application site reactions, somnolence, dizziness and headache.
Latvian: Nevēlamas blakusparādības (NBP), par kurām tika ziņots vairāk nekā 10% pacientu, kuri tika ārstēti ar Neupro transdermālo plāksteri ir šādas: slikta dūša, vemšana, reakcijas aplikācijas vietā, miegainība, reibonis un galvassāpes.
English: At the end of the maintenance treatment an improvement of at least 30% was seen in 60% of the subjects receiving rotigotine, 67% of the subjects receiving pramipexole and 35% of the subjects receiving placebo (Difference rotigotine versus placebo 25%, CI95% 13%; 36%, difference pramipexole versus placebo 32%, CI95% 21%; 43%, difference pramipexole versus rotigotine 7%, CI95% -2%; 17%).
Latvian: Uzturošās terapijas perioda beigās vismaz 30% uzlabošanās tika novērota 60% pacientu, kuri saņēma rotigotīnu, 67% pacientu, kuri saņēma pramipeksolu, un 35% pacientu, kuri saņēma placebo (starpība rotigotīnam pret placebo 25%, CI95%13%; 36%, starpība pramipeksolam pret placebo 32%, CI95% 21%; 43%, starpība pramipeksolam pret rotigotīnu 7%, CI95% -2%; 17%).
English: Tell your doctor if you notice any changes in behaviour, thinking or both that are listed above.
Latvian: Informējiet savu ārstu, ja Jūs novērojat jebkādas augstākminētās izmaiņas uzvedībā, domāšanā vai vai abos.
English: syncope, syncope vasovagal, loss of consciousness), dyskinesiae, dizziness posturale, lethargye, convulsion e
Latvian: (ieskaitot sinkopi, vazovagālu sinkopi, samaņas zudumu), diskinēzija, posturāls reibonis, letarģija
English: If you still get problems with your skin because of the patch, please see ‘Skin problems caused by the patch' in section 4 for more information.
Latvian: Ja Jums tomēr ir ādas kairinājums, ko izraisījis plāksteris, lai iegūtu vairāk informācijas, lūdzu skatīt 4. punktā ” Ādas problēmas, ko izraisījis plāksteris”.
English: The outside is tan-coloured and is imprinted with Neupro 1 mg/24 h or 3 mg/24 h.
Latvian: Ārējā puse ir dzeltenbrūnā krāsā ar uzdrukātu Neupro 1 mg/24 h vai 3 mg/24 h.
English: Side effects when using Neupro for Parkinson's disease Tell your doctor, pharmacist or nurse if you get any of the following side effects:
Latvian: Blakusparādības lietojiet Neupro Parkinsona slimības ārstēšanai: Pastāstiet savam ārstam,farmaceitam vai medmāsai, ja novērojat jebkuru no sekojošām blakusparādībām:
English: The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of Neupro in 7.2% of subjects.
Latvian: Lielākās daļas reakciju aplikācijas vietā intensitāte bija viegla vai vidēji izteikta, to novēroja tikai aplikācijas vietās un tā izraisīja ārstēšanas ar Neupro pārtraukšanu 7,2% pacientu.
English: Dopamine dysregulation syndromec, perception disturbancese
Latvian: Dopamīna disregulācijas sindroms c,
English: Diarrhoea c
Latvian: uzbudinājums d
English: How to use Neupro
Latvian: Kā lietot Neupro
English: Neupro 2 mg/24 h Neupro 4 mg/24 h Neupro 6 mg/24 h Neupro 8 mg/24 h Transdermal patch
Latvian: Neupro 2 mg/24 h Neupro 4 mg/24 h Neupro 6 mg/24 h Neupro 8 mg/24 h transdermāls plāksteris
English: The active substance is rotigotine.
Latvian: Aktīvā viela ir rotigotīns.
English: Each patch of 10 cm2 contains 4.5 mg of rotigotine.
Latvian: Katrs 10 cm2 plāksteris satur 4,5 mg rotigotīna.
English: erythema, pruritus, irritation, rash, dermatitis, vesicles, pain, eczema, inflammation, swelling, discolouration, papules, exfoliation, urticaria, hypersensitivity), asthenic conditions a
Latvian: (ieskaitot eritēmu, niezi, kairinājumu, izsitumus, dermatītu, vezīkulas, sāpes, ekzēmu, iekaisumu, pietūkumu, krāsas izmaiņas, pāpulas, nobrāzumus, nātreni, paaugstinātu jutību), astēniski stāvokļi a
English: Neupro 8 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 8 mg/24 h'.
Latvian: Neupro 8 mg/24 h transdermāls plāksteris Ārējais slānis ir dzeltenbrūnā krāsā ar uzdrukātu `Neupro 8 mg/24 h`.
English: 7 transdermal patches of Neupro 8 mg/24 h
Latvian: 7 transdermālos plāksterus Neupro 8 mg/24 h
English: How to use the Neupro patches
Latvian: Kā lietot Neupro plāksterus
English: hallucination, hallucination visual, hallucination auditory, illusion), nightmaree, paranoia e, confusional state e, psychotic disorder e, delusion e, delirium e
Latvian: (ieskaitot halucinācijas, redzes halucinācijas, dzirdes halucinācijas, ilūzijas), nakts murgi e, paranoja e, apjukums e, psihotiski traucējumi e,
English: The outside is tan-coloured and is imprinted with Neupro 4 mg/24 h, Neupro 6 mg/24 h or Neupro 8 mg/ 24 h.
Latvian: Ārējā puse ir dzeltenbrūnā krāsā ar uzdrukātu Neupro 4 mg/24 h, Neupro 6 mg/24 h vai Neupro 8 mg/24 h.
English: Hiccups e
Latvian: Hipotensija e
English: 7 transdermal patches of Neupro 4 mg/24 h
Latvian: 7 transdermālos plāksterus Neupro 4 mg/24 h
English: What Neupro is used for
Latvian: Kādam nolūkam Neupro lieto
English: Fall e a High Level Term b Observed in open-label studies c Observed during post-marketing d Observed in 2011 data pool of double-blind placebo-controlled studies e Observed in studies performed in patients with Parkinson's disease
Latvian: Novērots 2011 datu apkopojumos dubultaklos placebo kontrolētos pētījumos e Novērots pētījumos pacientiem ar Parkinsona slimību Parkinsona slimība
English: Talk to your doctor or pharmacist if you notice any of the side effects listed above.
Latvian: Sazinieties ar savu ārstu vai farmaceitu, ja Jūs novērojat jebkuru no augstāk minētajām blakusparādībām.
English: AST, ALT, GGT), weight increased, heart rate increased, CPK increasedd
Latvian: Paaugstināta aknu enzīmu koncentrācija (ieskaitot ASAT, ALAT, GGT), palielināta ķermeņa masa, paātrināta sirdsdarbība, paaugstināts KFK
English: 7 transdermal patches of Neupro 6 mg/24 h
Latvian: 7 transdermālos plāksterus Neupro 6 mg/24 h
English: Disturbances in consciousness NECa (incl.
Latvian: apziņas traucējumi NEC
English: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h'.
Latvian: Ārējais slānis ir dzeltenbrūnā krāsā ar uzdrukātu `Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h vai 8 mg/24 h`.
English: Neupro is a patch that is put on the skin.
Latvian: Neupro ir plāksteris lietošanai uz ādas.
English: • If you have forgotten to change the patch at your usual time, change it as soon as you remember
Latvian: Ja esat aizmirsis nomainīt plāksteri parastajā laikā Ja esat aizmirsis nomainīt plāksteri Jums parastajā laikā, nomainiet to, tiklīdz atceraties.
English: The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h.
Latvian: Ārējā puse ir dzeltenbrūnā krāsā ar uzdrukātu Neupro 2 mg/24 h.
English: Neupro 6 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 6 mg/24 h'.
Latvian: Neupro 6 mg/24 h transdermāls plāksteris Ārējais slānis ir dzeltenbrūnā krāsā ar uzdrukātu `Neupro 6 mg/24 h`.
English: Neupro 1 mg/24 h transdermal patch EU/1/05/331/038
Latvian: Neupro 1 mg/24 h transdermāls plāksteris EU/1/05/331/038
English: For most patients an effective dose is reached within 3 to 7 weeks at doses of 8 mg/24 h up to a maximum dose of 16 mg/24 h.
Latvian: Dažiem pacientiem efektīvā deva var būt 4 mg/24 h vai 6 mg/24 h. Lielākajai daļai pacientu efektīvā deva tiek sasniegta 3 līdz 7 nedēļu laikā, izmantojot devas no 8 mg/24 h, kas nepārsniedz maksimālo devu16 mg/24 h.
English: Neupro 1 mg/24 h transdermal patch Neupro 3 mg/24 h transdermal patch
Latvian: Neupro 1 mg/24 h transdermāls plāksteris Neupro 3 mg/24 h transdermāls plāksteris
English: Neupro 4 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 4 mg/24 h'.
Latvian: Neupro 4 mg/24 h transdermāls plāksteris Ārējais slānis ir dzeltenbrūnā krāsā ar uzdrukātu `Neupro 4 mg/24 h`.
English: Neupro 6 mg/24 h transdermal patch EU/1/05/331/007
Latvian: Neupro 6 mg/24 h transdermāls plāksteris EU/1/05/331/007
English: Neupro 4 mg/24 h transdermal patch Each patch releases 4 mg of rotigotine per 24 hours.
Latvian: Neupro 3 mg/24 h transdermāls plāksteris Katrs plāksteris 24 stundu laikā izdala 3 mg rotigotīna (rotigotine).
English: Each patch releases 1 mg of rotigotine per 24 hours.
Latvian: Katrs plāksteris 24 stundu laikā izdala 1 mg rotigotīna.
English: • Press the patch down firmly with the palm of your hand.
Latvian: • Stingri piespiediet plāksteri ar plaukstu.
English: The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h.
Latvian: Ārējā puse ir dzeltenbrūnā krāsā ar uzdrukātu 2 mg/24 h, 4 mg/24 h, 6 mg/24 h vai 8 mg/24 h.
English: Neupro 4 mg/24 h transdermal patch EU/1/05/331/004
Latvian: Neupro 4 mg/24 h transdermāls plāksteris EU/1/05/331/004
English: Neupro 1 mg/24 h transdermal patch Each patch releases 1 mg of rotigotine per 24 hours.
Latvian: KVALITATĪVAIS UN KVANTITATĪVAIS SASTĀVS Neupro 1 mg/24 h transdermāls plāksteris Katrs plāksteris 24 stundu laikā izdala 1 mg rotigotīna (rotigotine).
English: Neupro 8 mg/24 h transdermal patch EU/1/05/331/010
Latvian: Neupro 8 mg/24 h transdermāls plāksteris EU/1/05/331/010
English: EU/1/05/331/047 [7 transdermal patches] EU/1/05/331/049 [28 transdermal patches] EU/1/05/331/050 [30 transdermal patches] EU/1/05/331/058 [14 transdermal patches]
Latvian: EU/1/05/331/047 [7 transdermālie plāksteri] EU/1/05/331/049 [28 transdermālie plāksteri] EU/1/05/331/050 [30 transdermālie plāksteri] EU/1/05/331/058 [14 transdermālie plāksteri]
English: Weight decreased e, hepatic enzyme increasede (incl.
Latvian: Samazināta ķermeņa masa e, paaugstināta aknu enzīmu koncentrācija e
English: Neupro 3 mg/24 h transdermal patch EU/1/05/331/047
Latvian: Neupro 3 mg/24 h transdermāls plāksteris EU/1/05/331/047
English: • 8 mg/24 h: Each patch releases 8 mg of rotigotine per 24 hours.
Latvian: Neupro 8 mg/24 h transdermāls plāksteris Katrs plāksteris 24 stundu laikā izdala 8 mg rotigotīna (rotigotine).
English: EU/1/05/331/038 [7 transdermal patches] EU/1/05/331/040 [28 transdermal patches] EU/1/05/331/041 [30 transdermal patches] EU/1/05/331/056 [14 transdermal patches]
Latvian: EU/1/05/331/038 [7 transdermālie plāksteri] EU/1/05/331/040 [28 transdermālie plāksteri] EU/1/05/331/041 [30 transdermālie plāksteri] EU/1/05/331/056 [14 transdermālie plāksteri]
English: EU/1/05/331/010 [7 transdermal patches] EU/1/05/331/011 [28 transdermal patches] EU/1/05/331/033 [30 transdermal patches] EU/1/05/331/061 [14 transdermal patches]
Latvian: EU/1/05/331/010 [7 transdermālie plāksteri] EU/1/05/331/011 [28 transdermālie plāksteri] EU/1/05/331/033 [30 transdermālie plāksteri] EU/1/05/331/061 [14 transdermālie plāksteri]
English: Falle a
Latvian: Žagas e
English: syncope, syncope vasovagal, loss of consciousness), dyskinesia, dizziness postural, lethargy
Latvian: (ieskaitot sinkopi, vazovagālu sinkopi, samaņas zudumu), diskinēzija e,
English: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h'.
Latvian: Ārējais slānis ir dzeltenbrūnā krāsā ar uzdrukātu `Neupro 2 mg/24 h`.
English: EU/1/05/331/021 EU/1/05/331/024 EU/1/05/331/059
Latvian: EU/1/05/331/044 EU/1/05/331/056
English: Neupro 8 mg/24 h transdermal patch rotigotine
Latvian: Neupro 8 mg/24 h transdermāls plāksteris rotigotine
English: Neupro 4 mg/24 h transdermal patch Neupro 6 mg/24 h transdermal patch Neupro 8 mg/24 h transdermal patch
Latvian: Neupro 4 mg/24 h transdermāls plāksteris Neupro 6 mg/24 h transdermāls plāksteris Neupro 8 mg/24 h transdermāls plāksteris
English: Neupro 8 mg/24 h transdermal patch
Latvian: 8 mg/24 h transdermāls plāksteris
English: LABELLING AND PACKAGE LEAFLET
Latvian: Neupro ārējais izskats un iepakojums
English: EU/1/05/331/004 [7 transdermal patches] EU/1/05/331/005 [28 transdermal patches] EU/1/05/331/021 [30 transdermal patches] EU/1/05/331/059 [14 transdermal patches]
Latvian: EU/1/05/331/004 [7 transdermālie plāksteri] EU/1/05/331/005 [28 transdermālie plāksteri] EU/1/05/331/021 [30 transdermālie plāksteri] EU/1/05/331/059 [14 transdermālie plāksteri]
English: Neupro 1 mg/24 h transdermal patch rotigotine
Latvian: Neupro 1 mg/24 h transdermāls plāksteris rotigotine
English: EU/1/05/331/007 [7 transdermal patches] EU/1/05/331/008 [28 transdermal patches] EU/1/05/331/027 [30 transdermal patches] EU/1/05/331/060 [14 transdermal patches]
Latvian: EU/1/05/331/007 [7 transdermālie plāksteri] EU/1/05/331/008 [28 transdermālie plāksteri] EU/1/05/331/027 [30 transdermālie plāksteri] EU/1/05/331/060 [14 transdermālie plāksteri]
English: EU/1/05/331/001 [7 transdermal patches] EU/1/05/331/002 [28 transdermal patches] EU/1/05/331/015 [30 transdermal patches] EU/1/05/331/057 [14 transdermal patches]
Latvian: EU/1/05/331/001 [7 transdermālie plāksteri] EU/1/05/331/002 [28 transdermālie plāksteri] EU/1/05/331/015 [30 transdermālie plāksteri] EU/1/05/331/057 [14 transdermālie plāksteri]
English: Hiccups
Latvian: fotopsijae
English: Neupro 6 mg/24 h transdermal patch rotigotine
Latvian: Neupro 6 mg/24 h transdermāls plāksteris rotigotine
English: EU/1/05/331/018 [84 transdermal patches (3 packs of 28)]
Latvian: EU/1/05/331/018 [84 transdermālie plāksteri (3 kastītes pa 28)]
English: The strengths are 2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h for the treatment of Parkinson's disease.
Latvian: Ir pieejami šādi stiprumi Parkinosona slimības ārstēšanai: 2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h.
English: Sleep attacks/sudden onset of sleep, sexual desire disordersa (incl.
Latvian: Miega lēkmes/pēkšņa miega iestāšanās, dzimumtieksmes traucējumi a
English: EU/1/05/331/036 [84 transdermal patches (3 packs of 28)]
Latvian: EU/1/05/331/036 [84 transdermālie plāksteri (3 kastītes pa 28)]
English: EU/1/05/331/053 [84 transdermal patches (3 packs of 28)]
Latvian: EU/1/05/331/053 [84 transdermālie plāksteri (3 kastītes pa 28)]
English: • hiccups
Latvian: • caureja
English: Each patch releases 2 mg of rotigotine per 24 hours.
Latvian: Katrs plāksteris 24 stundu laikā izdala 2 mg rotigotīna.
English: EU/1/05/331/024 [84 transdermal patches (3 packs of 28)]
Latvian: EU/1/05/331/024 [84 transdermālie plāksteri (3 kastītes pa 28)]
English: Neupro 4 mg/24 h transdermal patch rotigotine
Latvian: Neupro 4 mg/24 h transdermāls plāksteris Rotigotine
English: Neupro 4 mg/24 h transdermal patch Rotigotine
Latvian: Neupro 4 mg/24 h transdermāls plāksteris rotigotine
English: EU/1/05/331/030 [84 transdermal patches (3 packs of 28)]
Latvian: EU/1/05/331/030 [84 transdermālie plāksteri (3 kastītes pa 28)]
English: EU/1/05/331/044 [84 transdermal patches (3 packs of 28)]
Latvian: EU/1/05/331/044 [84 transdermālie plāksteri (3 kastītes pa 28)]
English: • Your starting dose will be one 1 mg/24 h patch each day.
Latvian: • Jūsu sākotnējā deva būs viens Neupro 1 mg/24 h plāksteris katru dienu.
English: • Thigh or hip.
Latvian: • Augšstilbs vai gūža
English: Neupro is available in the following pack-sizes:
Latvian: Ir pieejami šādi Neupro iepakojumi:
English: Neupro 3 mg/24 h transdermal patch rotigotine
Latvian: Neupro 3 mg/24 h transdermāls plāksteris rotigotine
English: Neupro 2 mg/24 h transdermal patch rotigotine
Latvian: Neupro 2 mg/24 h transdermāls plāksteris rotigotine
English: A single daily dose should be initiated at 4 mg/24 h and then increased in weekly increments of 2 mg/24 h to an effective dose up to a maximum dose of 16 mg/24 h.
Latvian: Dozēšana pacientiem ar Parkinsona slimību vēlīnā stadijā ar mainīgu terapeitisko iedarbību: Vienreizējai sākuma dienas devai būtu jābūt 4 mg/24 h un pēc tam deva jāpalielina vienu reizi nedēļā pa 2 mg/24 h līdz efektīvai devai, kas nav lielāka par 16 mg/24 h.
English: Diarrhoeac
Latvian: Sirdsklauves
English: It is available as pink tablets (75 mg).
Latvian: Tās ir pieejamas kā rozā tabletes (75 mg).
English: Ref.: EMEA/356088/2009 EMEA/H/C/1053
Latvian: Atsauces dok.: EMEA/484221/2009 EMEA/H/C/1053
English: This means that Clopidogrel Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Latvian: Tas nozīmē, ka Clopidogrel Teva ir līdzīgas „atsauces zālēm”, kas jau ir reģistrētas Eiropas Savienībā (ES) ar nosaukumu Plavix.
English: This is then followed by the standard 75 mg dose once a day for at least four weeks (in ST segment elevation myocardial infarction) or for up to 12 months (in non-ST segment elevation syndrome).
Latvian: Tai seko 75 mg standartdeva vienreiz dienā vismaz četras nedēļas (miokarda infarkta ar ST pacēlumu pacientiem) vai līdz 12 mēnešiem (pacientiem bez ST segmenta pacēluma sindroma).
English: The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Teva to Teva Pharma B.V. on 28 July 2009.
Latvian: Eiropas Komisija 2009. gada 28. jūlijā izsniedza Clopidogrel Teva reģistrācijas apliecību, kas derīga visā Eiropas Savienībā, uzņēmumam Teva Pharma B.V.
English: In acute coronary syndrome, Clopidogrel Teva is used together with aspirin and treatment generally starts with a loading dose of four 75 mg tablets.
Latvian: Pacientiem ar akūtu koronāro sindromu Clopidogrel Teva jālieto kopā ar aspirīnu, un ārstēšana parasti jāsāk ar četru 75 mg tablešu piesātinošo devu.
English: Clopidogrel Teva is a ‘generic medicine'.
Latvian: Clopidogrel Teva ir „ģenēriskas zāles”.
English: Clopidogrel Teva can be started between seven days and six months after the stroke;
Latvian: Clopidogrel Teva terapiju var uzsākt septiņas dienas līdz sešus mēnešus pēc insulta;
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel Teva has been shown to have comparable quality and to be bioequivalent to Plavix.
Latvian: Cilvēkiem paredzēto zāļu komiteja (CHMP) secināja, ka saskaņā ar ES prasībām ir pierādīta Clopidogrel Teva un Plavix kvalitātes līdzvērtība un bioekvivalence.
English: Clopidogrel Teva can be given to the following groups of patients:
Latvian: Clopidogrel Teva var lietot šādas pacientu grupas:
English: The Committee recommended that Clopidogrel Teva be given marketing authorisation.
Latvian: Komiteja ieteica izsniegt Clopidogrel Teva reģistrācijas apliecību.
English: • patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
Latvian: • pacienti ar slimību, ko sauc par „akūtu koronāro sindromu”, kad šīs zāles jālieto kopā ar aspirīnu (citām zālēm, kas novērš trombu veidošanos), tostarp pacienti ar ievietotu stentu (īsu cauruli, kas ievietota artērijā, lai novērstu tās nosprostošanos).